However, outside MSI-H CRC, which accounts for only about 4% of advanced CSC patients, CSC stands out as one of the few cancers types where PD-1, PD-L1, and CTLA-4 inhibition immunotherapy has been unsuccessful
However, outside MSI-H CRC, which accounts for only about 4% of advanced CSC patients, CSC stands out as one of the few cancers types where PD-1, PD-L1, and CTLA-4 inhibition immunotherapy has been unsuccessful. proteins associated with the epithelial-to-mesenchymal transition (EMT) are most likely linked with the progression of cancer, and thus the cancer stem-cell…